JointHealth™ express October 1, 2013
Reminder: Patient input on treatment for rheumatoid arthritis needed
Do you have rheumatoid arthritis or care for someone who does? We want your valuable input.
On September 21, Arthritis Consumer Experts (ACE) sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR).
There is still time to get involved. The CDR continues to accept input on the manufacturer’s submission for the intravenous (IV) form of golimumab (Simponi®) for the treatment of rheumatoid arthritis.
If you live with rheumatoid arthritis or care for someone with the disease, please send us your input. Please provide your input by Thursday, October 3, 2013, so that we may submit a report by the October 4 deadline.
Please contact us at info@jointhealth.org to provide your input or arrange for a phone interview.
Reminder: Patient input on treatment for rheumatoid arthritis needed
Do you have rheumatoid arthritis or care for someone who does? We want your valuable input.
On September 21, Arthritis Consumer Experts (ACE) sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR).
There is still time to get involved. The CDR continues to accept input on the manufacturer’s submission for the intravenous (IV) form of golimumab (Simponi®) for the treatment of rheumatoid arthritis.
If you live with rheumatoid arthritis or care for someone with the disease, please send us your input. Please provide your input by Thursday, October 3, 2013, so that we may submit a report by the October 4 deadline.
Please contact us at info@jointhealth.org to provide your input or arrange for a phone interview.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.